A thiazole compound with potential antithrombotic activity.
A thiazole derivative, 4,5-bis(p-methoxyphenyl)-2-(trifluoromethyl)-thiazole was found to be a potent inhibitor of collagen-induced platelet aggregation, in vitro, using platelets from at at least six species, including man. It was active in human platelet-rich plasma at a concentration of 1 ng/ml. While its antiplatelet activity was greater than that of flurbiprofen, its cyclooxygenase activity was equivalent to that of flurbiprofen. Also, compared to flurbiprofen, the thiazole had less anti-inflammatory activity in the hind-paw edema test. The thiazole derivative inhibited platelet aggregation following oral administrative inhibited platelet aggregation following oral administration in five laboratory species. In the guinea pig it was active at 0.5 mg/kg. The LD50 in mice was greater than 1000 mg/kg (i.p.). This compound, which was designed through a systematic drug development program, may have high potential as an antithrombotic agent.
D000818:Animals; D004285:Dogs; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D013844:Thiazoles / Q000494:pharmacology*
D005343:Fibrinolytic Agents; D013844:Thiazoles; C035025:itazigrel